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Background: Proximal femur fracture (PFF) is associated with considerable morbidity and mortality. The European
Quality of Care Pathway (EQCP) study on PFF (NCT00962910) was designed to determine how care pathways (CP)
for hospital treatment of PFF affect consistency of care, adherence to evidence-based key interventions, and clinical
outcome.
Methods/Design: An international cluster-randomized controlled trial (cRCT) will be performed in Belgium, Ireland,
Italy and Portugal. Based on power analyses, a sample of 44 hospital teams and 437 patients per arm will be
included in the study. In the control arm, usual care will be provided. Experimental teams will implement a care
pathway which will include three active components: a formative evaluation of quality and organization of the care
setting, a set of evidence-based key interventions, and support of the development and implementation of the CP.
Main outcome will be the six-month mortality rate.
Discussion: The EQCP study constitutes the first international cRCT on care pathways. The EQCP project was
designed as both a research and a quality improvement project and will provide a real-world framework for
process evaluation to improve our understanding of why and when CP can really work.
Trial registration number: NCT00962910Background
Fracture of the proximal femur constitutes one of the
most devastating complications of osteoporosis. Within
the European Union, more than 400,000 women and
100,000 men sustain a hip fracture every year [1]. The
worldwide annual number of hip fractures amounts to
about 1,800,000. Because the number of elderly people is
rising, a continued increase in incidence of fractures is
expected [1]. People with a proximal femur fracture ex-
perience a clinically important decline in functional sta-
tus with considerable loss in quality of life [2,3]. Within
one year after sustaining a hip fracture, close to 20% of
individuals will have to be institutionalized because of
the fracture and because of its functional consequences.* Correspondence: kris.vanhaecht@med.kuleuven.be
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distribution, and reproduction in any mediumOverall, hip fractures represent one of the main causes
of hospitalization, institutionalization, and mortality in
old age [4]. According to a meta-analysis published in
2010, older adults have a 5- to 8-fold increase in their
risk of all-cause mortality during the first 3 months after
hip fracture (3). This excess mortality persists over time,
even 10 years after sustaining the fracture; both women
and men are affected, although, at any given age, excess
annual mortality after hip fracture is higher in men than
in women [3].
Organizing and standardizing the care process for
these patients, with a focus on quality, efficiency, and ac-
cessibility should be one of the priorities over the next
few years for clinicians, healthcare managers, and policy
makers. One of the methods to (re)organize a care
process is the development and implementation of a
care pathway. Care pathways, also known as clinical
pathways or critical pathways, are used worldwide for a
variety of patient groups [5-13]. A care pathway istral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Vanhaecht et al. BMC Health Services Research 2012, 12:124 Page 2 of 8
http://www.biomedcentral.com/1472-6963/12/124defined as a complex intervention for mutual decision
making and organization of predictable care for a well-
defined group of patients during a well-defined period.
Defining characteristics of pathways include: explicitly
stating the goals and key elements of care based on evi-
dence, best practice and patient expectations; facilitating
communication and coordination of roles and sequen-
cing the activities of the interprofessional care team;
optimizing communication with patients and their rela-
tives; documenting, monitoring, and evaluating variances
and outcomes; and, finally, identifying relevant resources
[12,14-16].
A care pathway is explicitly defined as a “complex
intervention” [12,17-19]. Complex interventions, also
known as multi-component interventions, have been
built from a number of components that may act both
independently and interdependently [20,21]. Although
they may be difficult to specify, these interacting compo-
nents seem essential for the proper functioning of the
intervention. Considering a spectrum of low to high
complexity, developing a drug would be at the low end
of the spectrum while assessing the effect of a stroke
unit would be at the high end. The more it is difficult to
exactly define the “active components” of an interven-
tion and how these interrelate, the more it is likely that
the intervention is a complex one [19,20,22]. Care path-
ways seem to be at the higher end of the complexity
spectrum. Typical active ingredients of a care pathway
include the promotion of interdisciplinary teamwork,
the integration of a package of evidence-based key inter-
ventions, and the active follow-up of care processes
[6,12,13,23,24].
A recent Cochrane review concluded that care path-
ways result in reduced in-hospital complications and
improved documentation, without negatively impacting
length of stay or hospital costs [25]. However, these
effects may vary widely and may not always meet expec-
tations. To gain insight into the active components of
complex care pathways, one needs to evaluate the con-
text of the interventions and the mechanisms involved
[14,20,21,26,27]. Multicenter trials that include these
evaluations are critical to fully understand how and
when care pathways are effective [12,28,29].
A literature search identified six reviews on the effect
of pathways in patient groups that included hip fracture
patients [25,30-34]. Because various types of patients
were included in the reviews by Rotter et al. (2008,
2010), it was not possible to address any effect on hip
fracture patients specifically [25,30]. A more patient-
specific meta-analysis by Neuman et al. (2009) was li-
mited by the lack of a common definition and concept
on care pathway [31] and did not allow a formal com-
parison of the outcomes of the included studies. More-
over, in many of the primary studies included in thereviews, the components of the complex interventions
were not always described [32-34]. Therefore, even when
a care pathway was developed, many of the observed
results could not be attributed directly to the pathway.
Also, study designs were substantially different. Despite
these limitations, the major conclusion that emerged
from these reviews is that care pathways can significantly
reduce the length of stay and have a positive impact on
different outcomes. The results also suggest that morta-
lity in hip fracture patients may not be the best para-
meter to assess quality of care as they may ignore
important improvements in other outcomes that can be
achieved by care pathways. Additional research is needed
to evaluate the impact of care pathways on quality of
care and clinical outcome in hip fracture patients.
To evaluate care pathway effectiveness, the European
Pathway Association (E-P-A), an international not-for-
profit association, launched the European Quality of
Care Pathways (EQCP)-study on proximal femur frac-
ture. Earlier, E-P-A launched a similar study on exacer-
bation of chronic obstructive pulmonary disease (COPD)
[12,29].
Objectives
The primary goal of the EQCP study on PFF is to eva-
luate care pathway effectiveness in the acute hospital set-
ting. A secondary goal is to understand how and under
what circumstances the implementation of a pathway for
PFF is successful [29].
Methods/Design
The project
The European Quality of Care Pathways (EQCP) study is
an international multicentre research project launched
by the European Pathway Association (E-P-A) (http://
www.E-P-A.org) [35]. The E-P-A is collaborating with
the Center for Health Services and Nursing Research of
the Faculty of Medicine of Leuven University (Belgium)
and the School of Public Health of the Amedeo
Avogadro University of Eastern Piedmont (Italy), which
is taking the scientific lead in this study. The study will
be executed in four countries: Belgium, Ireland, Italy
and Portugal. In each country, a research centre is co-
ordinating the project based on an internationally agreed
protocol. In Belgium, the lead coordinating centre is the
Center for Health Services and Nursing Research of the
Faculty of Medicine of Leuven University. For Ireland,
the lead centre is the Health Service Executive in Dublin.
In Italy, the School of Public Health of the Amedeo
Avogadro University of Eastern Piedmont is coordina-
ting the project with support from ARESS Piemonte. In
Portugal, the lead coordinating centre is the National
School of Public Health in Lisbon. In each of the four
countries, hospitals will be selected by E-P-A in close
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ticipating hospital, a study coordinator will be appointed
to facilitate implementation of the care pathway. The
study coordinator will be trained by the E-P-A team on
how to develop and implement care pathways [12,29].
Study design
To evaluate the effect of a care pathway, a cluster-
randomized controlled trial (cRCT) will be conducted
[12,17,18,20,22,36] (Figure 1). In cRCTs, organizations ra-
ther than individuals are randomized to an intervention
and a control group, and outcomes are measured on an in-
dividual level within the clusters [20]. Each cluster consists
of patients hospitalized for PFF in a particular hospital and
cared for by a specific interprofessional care team.
Stratified randomization will be used to assign hospitals
to an intervention group (development and implementa-
tion of an evidence-based care pathway) and a control
group (no intervention/usual care). To ensure that clus-
ters in both arms are in balance, clusters will be stratified
according to country-level, hospital type (teaching versus
non teaching), hospital size (<600 and ≥600 beds), and an-
nual volume of patients (<300 and ≥300 patients). Hospi-
tals included in the control group will have the
opportunity to develop a care pathway one year later,
based on the protocol and experience gained in the ex-
perimental group. Through this process, a network of
high-performing organizations for PFF can be built.
Inclusion – exclusion criteria
Organizations are included if the hospital management
and the patient care team provide written consent to
participate and, when randomized in the control group,
agree not to develop and implement a pathway for PFF
within the time frame of the study. All patients consecu-
tively admitted for PFF will be considered for inclusionFigure 1 The EQCP study design.based on the following criteria: (i) provide written
informed consent; (ii) minimum age of 65 years; (iii)
closed fracture; (iv) eligible for surgical intervention; (v)
American Society of Anesthesiology score 1, 2, or 3; and
(vi) able to communicate in the native language. Each
patient will be included only once in the study, at the
initial admission, even if a patient is rehospitalized du-
ring the enrollment period. Exclusion criteria are: (i) se-
vere dementia (based on DSM IV-criteria); pathological
fracture; or a peri-prosthetic fracture.
Study sample
Sample size calculation in a cRCT was based on the
expected improvement in the main outcome variables
[12,17,18,20,22]. The selection of main outcomes for the
EQCP-study was based on three criteria: frequency of
use in the literature, expert opinion and timing of the re-
search project with respect to organizational constraints
(sustainability of the design, time to include patients).
Based on these criteria, six-month mortality rate was
identified as the main study outcome for in-hospital
management of PFF. Based on a power of 80% and an α
of 0.05 (two-sided), it was calculated in StatisticaW that
325 patients per arm are needed to observe a reduction
from 15% to 8% [37,38]. After adjustment for the cluster
design, based on two previous cRCTs by Panella et al.
[17,18] (ICC: 0.018; IFF: 1.342; n = 20), the effective sam-
ple size increased to 437 patients per arm. Assuming a
number of 20 consecutive admitted patients in each
unit, 22 hospitals need to be included in each interven-
tion and control group [17,18].
The complex intervention: care pathway implementation
in the intervention arm
The care pathway will include three active components.
(i) The first component is a formative evaluation of the
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performed by measuring performance on key interven-
tions (see Figure 2) [12,39]. The formative evaluation is
an evaluation of the actual performance of the care
process in each of the experimental clusters. This eva-
luation is led by local contact persons who each followed
a workshop. The goal of this workshop was to inform
the contact persons and to standardize the procedure.
Du ring this one day workshop the national coordinator,
supported by the international research team, presented
how and what to evaluate. The main focus was the
multidisciplinary teamwork and the performance of the
key interventions. Key interventions are those that have
a significant impact on patient outcomes. These are per-
formed by all professional groups within the patient care
team that treats PPF patients, i.e., orthopedic surgeons,
geriatricians, nurses, physiotherapists, and social work-
ers. Key interventions are performed in the domains of
pre- peri-, and postoperative care and include patient as-
sessment, appropriate medication, execution of essential
laboratory tests and medical imaging, passive and active
mobilization, pain management, discharge management
and patient information. Feedback will be provided on
the data obtained to help the teams understand their
performance on process indicators as potential areas for
improvement and redesign of the actual care process. To
this end, a formal evaluation will be performed before
developing the care pathway. During this evaluation,
performance on a set of key-interventions will be mea-
sured in 20 consecutive patients (see ii). All data will be
transferred to the research center for analysis. A feed-
back report will be provided to allow the teams to
benchmark their performance compared to all other
teams participating in the study. (ii) A set of evidence-
based key interventions will be provided to the team.
This set will be based on an extensive literature review,
Map of MedicineW (http://www.mapofmedicine.com),
and consensus among international clinical experts using





























Figure 2 The EQCP complex intervention.will include both in-hospital interventions and informa-
tion for a safe discharge. In this second part of the inter-
vention, each of the experimental teams will receive and
discuss a feedback report. This feedback report will pro-
vide information on the actual performance (see i). Per
team a local contact person and 2 representatives of the
team are invited to a seminar. During this seminar the
international coordinator, supported by the national co-
ordinator will present the findings. The lead in this sem-
inar is with the international coordinator to make sure
the data are presented in a standardized way. (iii) All
study coordinators will be trained to improve the
organization of the care process by developing and
implementing a care pathway, based on the evaluation of
the care process and the set of evidence-based key inter-
ventions. In the training workshops, a care pathway im-
plementation protocol will be used that is based on the
Deming-PDSA cycle, a generally accepted standard
method for quality improvement [40]. This workshop
will be led by the international coordinator. He will be
supported by local experts in care pathways who each
followed a five day international summer school on the
development, implementation and evaluation of care
pathways [41]. This summer school was organized by
the European Pathway Association [35].
During the intervention different meetings with the
study coordinators and team member representatives
will be organized to present and discuss the feedback re-
port and to discuss actual bottlenecks in implementing
the care pathway. Change will be promoted by exchan-
ging best practices among participants. During these
meetings, local clinical champions and team change
experts will help and stimulate the study coordinators to
effectively share knowledge [12,29].
Along with randomized controlled trials, in complex
interventions, qualitative methods such as process eva-
luations are advised to promote quality care [42]. In this
regard, the context in which the care pathway was deve-




Development  and 
implementation




















Vanhaecht et al. BMC Health Services Research 2012, 12:124 Page 5 of 8
http://www.biomedcentral.com/1472-6963/12/124evaluated using qualitative, observational approaches
(e.g., semi-structured interviews with key stakeholders)
during and after pathway-implementation.
The control group
In the control group, the complex intervention will not
be implemented and the teams will provide usual care.
Control hospitals agree not to develop a care pathway
during the study period.
Measurements
To measure the effect of the care pathways, a set of
process and outcome indicators for PFF were developed.
The primary outcome measure is 6-month Mortality.
Next to this indicator the following mortality indicators
were defined: in-acute orthopedic ward mortality, overall
in-hospital mortality, in-hospital mortality before surgi-
cal intervention, overall operative-theatre mortality, in-
hospital mortality after surgical intervention, 30-day
mortality. Next to mortality other secondary outcome
measures were defined: a) Readmission: 30-days re-
admission, 6-month readmission, b) Length of stay:
interval time between admission and surgery (anesthetic
induction), overall operative-theatre time, length of stay
in the orthopedic ward, overall in-hospital length of
stay; c) In-hospital pain score at 24 and 48 h post-
operatively and at discharge d) Postoperative complica-
tions during hospitalization, e) Functional status at
discharge, f ) Mobility status at discharge, g) Proportion
of patients returning to previous home status after dis-
charge, h) Health Related Quality of Life (HRQL).
As one of the goals of care pathways is to enhance the
compliance to evidence based components of treatment,
next to outcome measures a set of process indicators
were defined. We used the same methodology as for the
outcome indicators by screening the international guide-
lines and performing an international Delphi study. The
process indicators are: a) Risk assessment of pressure
sores/ulcers, b) Prevention of pressure sores/ulcers, c)
Surgery within 24 h after admission, d) Performance of
X-ray pre-operatively, e) Pré-operative care and assess-
ment: ensure general analgesia is adequate, f ) Pré-
operative care and assessment: assessment of anemia, g)
Antithrombotic prophylaxis, h) Antibiotic prophylaxis, i)
Assessment of cognitive status: at admission, postopera-
tively at start of mobilization, j) Assessment of nutri-
tional status, k) Management of nutritional status, l)
Mobilization within 24 h postoperatively, m) Geriatric
Assessment pré-operatively, n) osteoporosis screening
and management and o) discharge management.
These indicators were translated during a consensus
meeting in actual measurements by a multidisciplinary
expert panel, consisting of a geriatrician, an orthopedic
surgeon, a physiotherapist, a clinical nurse specialist,and researchers of the EQCP-study [12,29]. To further
understand why pathways work, information on the con-
text of the organization is important. Within the EQCP
study, a set of both generic and PFF-specific context
indicators and team structure indicators was developed
based on literature review, an international Delphi study,
and expert opinion [12,29]. The literature searches and
the international Delphi studies on both the outcome
and process measures will be submitted as separate
international publications as part of the EQCP research
output. The details on each of the indicators (definition,
numerator, denominator, inclusion & exclusion criteria)
will be downloadable from the website of the European
Pathway Association (www.E-P-A.org) as soon as the
data of the study will be collected. In this way these indi-
cators can be used by other teams who are in search for
analyzing and optimizing their processes of care.
Registration and ethical approval
The study has been registered as a cRCT at clinicaltrials.
gov (identifier: NCT00962910). The ethical approval will
be country-specific, but overall ethical approval will be
obtained on three levels: (i) Ethical approval by the ethi-
cal committee of the coordinating centre on a country
level; (ii) Ethical approval with regard to the participa-
tion in the intervention on a cluster level, i.e. by the
ethical committee of each of the participating hospitals.
These committees can agree or disagree with the overall
approval of the coordinating centre. As indicated by the
Medical Research Council, patient’s consent to partici-
pate in the study is not possible, because randomization
occurred at the hospital level and not on the patient
level. Moreover, the aim of the study is to improve ad-
herence to evidence-based care through care pathways
in the intervention group. In the control group, no inter-
vention will be implemented and patients will only re-
ceive usual care. Participating in the intervention or
control group should not imply any risk for the patients
included; and (iii) Individual informed consent will be
obtained from the patient with regard to the access of
his/her record and participation in surveys. Approval of
the ethical committee of the coordinating centre at
Leuven University has already been obtained (identifier:
ML5618/B32220096038) while approval in Portugal,
Italy and Ireland is pending.
Discussion
The EQCP study is the first international cluster-
randomized controlled trial on the effect of care path-
ways in two specific patient groups: chronic obstructive
pulmonary disease and proximal femur fractures, re-
spectively. Three active components define the complex
intervention: feedback on the actual performance, infor-
mation on the evidence-based key interventions, and the
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combined with a realistic evaluation approach [26]. This
allows analysis of the differences between the interven-
tion and control groups in process and outcome indica-
tors and evaluation of the context and implementation
process in the intervention group [43]. As suggested by
Berwick in 2008, it is not only important to understand
if an intervention works but also why and under what
circumstances it works [21]. The approach in the EQCP
study will allow us to analyze if pathways work but also
provide information on the when and how [29]. Hawe
and colleagues argued that the crucial point in evalua-
ting complex interventions lies in what is standardized.
In complex interventions, standardization should not
only apply to the components but also to the function
and process of the intervention [44]. This is particularly
important in pathway research as previously described
by Panella et al. [28]. Rather than defining the compo-
nents of the intervention as standard, what should be
defined as standard are the steps in the change process
[44]. In pathway research, the implementation process—a
quality improvement cycle—that is executed is part of the
intervention and that is why the improvement and imple-
mentation process is included as one of the basic active
ingredients. One challenge in multicenter trials on care
pathways—as well as in quality improvement methods in
general—is to understand the context. Pawson and Tilley
defined an action as causal only if its outcome is triggered
by a mechanism acting in a specific context (context +
mechanism = outcome) [26]. They argued that programs
work (i.e., have good outcomes) to the extent that they
introduce appropriate ideas and opportunities (the me-
chanism) to groups in the appropriate social and cultural
conditions (the context) [21,26]. This realistic evaluation
paradigm has already been used in pathway research
[12,15,45] and was recently promoted by Berwick [21]. In
pathways, the mechanism will need to be based on the
basic active components as described above but the fine-
tuning of the intervention will be based on the actual
performance challenges and on the context of the
organization and team involved. To fully understand what
is happening while developing and implementing a care
pathway, a set of team indicators and organizational fac-
tors will be measured and qualitative approaches will be
used [23]. Process and outcome indicators will provide
data to understand if pathways work, but the team indica-
tors will be of help in understanding why and how they
work. The design of this part of the study is currently
being prepared and will be published later.
One important measure to analyze in this study will
be the variation and impact of the length of stay on the
outcomes, as this could lead to a difference in dose of
the intervention. To analyze this issue and based on the
discussions within the international research team andwith the coordinators and clinicians in each of the par-
ticipating countries, we included a set of measures on
the length of stay and the process-flow. For each of the
patients data are collected on the time a patient arrives
in the hospital, the timing of the operation, the post-
operative activities and the time of discharge. In this way
we will be able to not only analyze the relation between
the pre-operative and overall length of stay and the pre-
defined process and outcome indicators, but we will also
be able to analyze the variation within each of the sites,
and between the sites in each country using a multilevel
statistical approach. Additionally these data will provide
information on the variation of the processes of care in
these four European countries.
With this study, the European Pathway Association
will be able to help health professionals and hospital
managers in actively improving their quality and effi-
ciency of care [29]. All findings will be reported as out-
lined in the CONSORT statement [46]. The teams will
receive support in re-organizing the PFF-care processes
and potentially use this implementation knowledge in
other care processes. Teams will receive feedback on
their actual performance including benchmark data
compared to other international teams. As a result, an
international network of high-performing teams on PFF
will be built, making the EQCP project both a research
study and a quality improvement project.
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